Q-omics provides the consensus-scored RASSF7 profile across patient tissues and cancer cell-line models. RASSF7 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RASSF7 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, RASSF7 protein abundance shows 28,162 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KICH, and LSCC as cancer lineages where RASSF7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RASSF7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RASSF7 survival associations across molecular data types. RASSF7 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (1) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RASSF7 RNA expression–survival associations across cancer types. High RASSF7 expression shows unfavorable associations in ACC, GBM, LGG, LIHC and UCS, but favorable associations in SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RASSF7 RNA expression.
This table summarizes RASSF7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 11. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RASSF7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RASSF7 shows lower tumor expression in KICH and higher tumor expression in LIHC, BLCA, COAD, STAD and BRCA. The KICH box plot shows higher RASSF7 RNA expression in normal versus tumor tissue (log2 FC = −1.601, t-test p < 0.001).
This table shows molecular features associated with RASSF7 in patient tissues and cancer cell lines. In patient samples, RASSF7 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RASSF7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
